Ultragenyx Pharmaceutical Inc. Stock
There is an upward development for Ultragenyx Pharmaceutical Inc. compared to yesterday, with an increase of €0.27 (1.190%).
With 26 Buy predictions and not a single Sell prediction Ultragenyx Pharmaceutical Inc. is an absolute favorite of our community.
With a target price of 50 € there is potential for a 117.86% increase which would mean more than doubling the current price of 22.95 € for Ultragenyx Pharmaceutical Inc..
Pros and Cons of Ultragenyx Pharmaceutical Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
S********** s********
?
C******** o* t** e**********
Cons
?
M***** P*******
?
B****
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Ultragenyx Pharmaceutical Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. | 1.190% | -3.653% | -18.034% | -9.280% | 35.000% | -34.828% | -71.108% |
| Ligand Pharmaceuticals | -0.800% | 0.787% | -0.775% | 93.939% | 54.217% | 306.349% | 173.329% |
| United Therapeutics | 0.670% | -7.275% | -6.855% | 61.533% | 1.123% | 100.046% | 151.221% |
| Ionis Pharmaceuticals Inc. | -0.810% | 1.290% | 3.623% | 32.229% | -27.192% | 34.896% | 46.999% |
Comments
Ultragenyx Pharmaceutical (RARE) had its "buy" rating reaffirmed by HC Wainwright. They now have a $50.00 price target on the stock.
Show more
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical (RARE) had its price target lowered by Wells Fargo & Company from $47.00 to $45.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical (RARE) had its price target lowered by Guggenheim from $43.00 to $35.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
News
Ultragenyx Pharmaceutical Q2 Earnings Call Highlights
Key Points
- Interested in Ultragenyx Pharmaceutical Inc.? Here are five stocks we like better.
- Ultragenyx reported record Q2 revenue of $214 million, led by Crysvita’s $156 million contribution
What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year
On May 14, 2026, Krensavage Asset Management disclosed it bought 241,245 shares of Ultragenyx Pharmaceutical (NASDAQ:RARE), an estimated $5.43 million trade based on quarterly average pricing.
